<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03116516</url>
  </required_header>
  <id_info>
    <org_study_id>YHP1604-102</org_study_id>
    <nct_id>NCT03116516</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Compare the Safety and Pharmacokinetics of YHP1604 in Comparison to the Co-administration of Telmisartan/Amlodipine and Rosuvastatin</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, Crossover Clinical Trial to Compare the Safety and Pharmacokinetics of YHP1604 in Comparison to the Co-administration of Telmisartan/Amlodipine and Rosuvastatin in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, open label, single-dose, crossover study to investigate the
      pharmacokinetics of YHP1604 in comparison to the co-administration of telmisartan/amlodipine
      and rosuvastatin in healthy male volunteers

      Hypothesis: &quot;YHP1604&quot; and &quot;telmisartan/amlodipine and rosuvastatin&quot; are showing equal
      pharmacokinetics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1, open label, single-dose, crossover study to investigate the
      pharmacokinetics of YHP1604 in comparison to the co-administration of telmisartan/amlodipine
      and rosuvastatin in healthy male volunteers.

      In ARM1, 30 subjects will be assigned and the subjects will be administered
      &quot;telmisartan/amlodipine and rosuvastatin&quot; at Day1 and &quot;YHP1604&quot; at Day22.

      In ARM2, 30 subjects will be assigned and the subjects will be administered &quot;YHP1604&quot; at Day1
      and &quot;telmisartan/amlodipine and rosuvastatin&quot; at Day22.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2017</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A randomized, open-label, single dose, crossover clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Telmisartan/Amlodipine/Rosuvastatin Cmax, AUClast</measure>
    <time_frame>0 - 72 hrs, 0 - 168 hrs, 0 - 48 hrs</time_frame>
    <description>Cmax, AUClast</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Hypertension</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>ARM1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In ARM1, 30 subjects will be assigned and the subjects will be administered &quot;telmisartan/amlodipine and rosuvastatin&quot; at Day1 and &quot;YHP1604&quot; at Day22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In ARM2, 30 subjects will be assigned and the subjects will be administered &quot;YHP1604&quot; at Day1 and &quot;telmisartan/amlodipine and rosuvastatin&quot; at Day22.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temisartan/Amlodipine+Rosuvastatin</intervention_name>
    <description>All subjects will receive a single oral dose of temisartan/amlodipine+rosuvastatin administered in the morning.</description>
    <arm_group_label>ARM1</arm_group_label>
    <arm_group_label>ARM2</arm_group_label>
    <other_name>Twynsta Tab.+Crestor Tab.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YHP1604</intervention_name>
    <description>All subjects will receive a single oral dose of YHP1604 administered in the morning.</description>
    <arm_group_label>ARM1</arm_group_label>
    <arm_group_label>ARM2</arm_group_label>
    <other_name>FDC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male with body mass index(BMI) between 18.5 and 30 kg/m2

          -  Who has not suffered from clinically significant disease

          -  Provision of signed written informed consent

        Exclusion Criteria:

          -  History of and clinically significant disease

          -  A history of drug abuse or the presence of positive reactions to drugs that have abuse
             potential in urine screenings for drugs

          -  Administration of other investigational products within 3 months prior to the first
             dosing

          -  Volunteers considered not eligible for the clinical trial by the investigator due to
             reasons including laboratory test results, ECGs, or vital signs
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Healthy male with body mass index(BMI) between 18.5 and 30kg/m2</gender_description>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mingul Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mingul Kim, MD</last_name>
    <phone>MD</phone>
    <email>mgkim@jbcp.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingul Kim, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2017</study_first_submitted>
  <study_first_submitted_qc>April 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2017</study_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

